BioAge Labs (NASDAQ:BIOA) Stock Rating Upgraded by Wall Street Zen

BioAge Labs (NASDAQ:BIOA) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Sunday.

BIOA has been the topic of several other reports. Citigroup increased their target price on shares of BioAge Labs from $10.00 to $15.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioAge Labs in a report on Thursday, October 30th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, BioAge Labs currently has an average rating of “Hold” and a consensus target price of $15.00.

BioAge Labs Stock Down 6.3%

Shares of BioAge Labs stock opened at $20.16 on Friday. The business has a fifty day simple moving average of $12.22 and a 200 day simple moving average of $7.66. The stock has a market cap of $722.84 million, a PE ratio of -13.26 and a beta of 1.38. BioAge Labs has a 12 month low of $2.88 and a 12 month high of $24.00.

BioAge Labs (NASDAQ:BIOA) last posted its earnings results on Thursday, November 6th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.67) by $0.11. The company had revenue of $2.05 million for the quarter.

Insider Transactions at BioAge Labs

In related news, insider Paul D. Rubin sold 18,000 shares of the stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $12.00, for a total transaction of $216,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Dov A. Md Goldstein sold 27,000 shares of the firm’s stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $19.70, for a total transaction of $531,900.00. Following the completion of the transaction, the chief financial officer directly owned 22,408 shares of the company’s stock, valued at approximately $441,437.60. This trade represents a 54.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 347,004 shares of company stock valued at $5,673,859 over the last 90 days. 20.82% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On BioAge Labs

A number of hedge funds and other institutional investors have recently bought and sold shares of BIOA. Vanguard Group Inc. raised its stake in BioAge Labs by 6.0% in the third quarter. Vanguard Group Inc. now owns 1,651,247 shares of the company’s stock valued at $9,709,000 after buying an additional 93,694 shares during the period. Geode Capital Management LLC lifted its holdings in BioAge Labs by 60.8% during the 2nd quarter. Geode Capital Management LLC now owns 453,455 shares of the company’s stock valued at $1,873,000 after purchasing an additional 171,426 shares during the last quarter. Millennium Management LLC lifted its holdings in BioAge Labs by 749.8% during the 3rd quarter. Millennium Management LLC now owns 306,552 shares of the company’s stock valued at $1,803,000 after purchasing an additional 270,479 shares during the last quarter. Marshall Wace LLP boosted its position in BioAge Labs by 324.7% during the second quarter. Marshall Wace LLP now owns 226,789 shares of the company’s stock worth $937,000 after purchasing an additional 173,388 shares during the period. Finally, Stonepine Capital Management LLC increased its holdings in shares of BioAge Labs by 202.2% in the second quarter. Stonepine Capital Management LLC now owns 151,085 shares of the company’s stock valued at $624,000 after purchasing an additional 101,085 shares during the last quarter.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.